This supplemental funding from the NIA is being put to use immediately,” Spurlock said. “We are recruiting patient specimens, doing the analysis, and looking for the signals in blood that could be early biomarkers for Alzheimer’s and then trying to identify the distinct patterns for Alzheimer’s in age-matched healthy controls – versus dementia versus mild cognitive impairment – so that we can appropriately ‘bucket’ and triage these patients at a molecular level.”

We’ll collect our data and then once the data is collected in the coming months, we’re going to apply analytics and machine learning strategies to build models that can effectively discriminate and distinguish these diseases.

Read more of this article from Medtech Insights.